Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ALETA-001 |
Synonyms | |
Therapy Description |
ALETA-001 is a chimeric antigen receptor (CAR) T-cell engager protein that binds to CD20 expressed on B-cell tumor cells and enhances display of CD19 on tumor cells, potentially leading to increased T-cell activation and induction of cytotoxicity against tumor cells (Blood (2021) 138 (Supplement 1): 1713). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ALETA-001 | ALETA 001|ALETA001 | ALETA-001 is a chimeric antigen receptor (CAR) T-cell engager protein that binds to CD20 expressed on B-cell tumor cells and enhances display of CD19 on tumor cells, potentially leading to increased T-cell activation and induction of cytotoxicity against tumor cells (Blood (2021) 138 (Supplement 1): 1713). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06045910 | Phase Ib/II | ALETA-001 | A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies | Recruiting | GBR | 0 |